Relevance of focal osseous uptake on FDG PET with or without CT changes in oncology patients

2017 ◽  
Vol 42 ◽  
pp. 138-146
Author(s):  
Gunjan Garg ◽  
Raphaella DaSilva ◽  
Mimi Kim ◽  
Charito Love ◽  
Tony Abraham
Keyword(s):  
Fdg Pet ◽  
Oncology Patients

Total-body 18F-FDG PET/CT scan in oncology patients: how fast could it be?

2021 ◽  
Author(s):  
Pengcheng Hu ◽  
Yiqiu Zhang ◽  
Haojun Yu ◽  
Shuguang Chen ◽  
Hui Tan ◽  
...  
Keyword(s):  
Ct Scan ◽  
Fdg Pet ◽  
Oncology Patients ◽  
Pet Ct ◽  
18F Fdg ◽  
Total Body ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

scholarly journals Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients

2021 ◽  
Vol 35 (11) ◽  
pp. 1264-1269 ◽  
Author(s):  
Pooja Advani ◽  
Saranya Chumsri ◽  
Tanmayi Pai ◽  
Zhuo Li ◽  
Akash Sharma ◽  
...  
Keyword(s):  
Immune Response ◽  
Lymph Nodes ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Time Course ◽  
Metabolic Response ◽  
Standard Of Care ◽  
Oncology Patients ◽  
Absolute Change

Abstract Background mRNA COVID-19 vaccines are known to provide an immune response seen on FDG PET studies. However, the time course of this metabolic response is unknown. We here present a temporal metabolic response to mRNA COVID-19 vaccination in oncology patients undergoing standard of care FDG PET. Methods 262 oncology patients undergoing standard of care FDG PET were included in the analysis. 231 patients had at least one dose of mRNA COVID-19 vaccine while 31 patients had not been vaccinated. The SUVmax of the lymph nodes ipsilateral to the vaccination was compared to the contralateral to obtain an absolute change in SUVmax (ΔSUVmax). Results ΔSUVmax was more significant at shorter times between FDG PET imaging and COVID-19 mRNA vaccination, with a median ΔSUVmax of 2.6 (0–7 days), 0.8 (8–14 days), and 0.3 (> 14 days), respectively. Conclusion Consideration should be given to performing FDG PET at least 2 weeks after the COVID-19 vaccine.

Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients

2008 ◽  
Vol 44 (12) ◽  
pp. 1678-1683 ◽  
Author(s):  
Marta Zafra ◽  
Francisco Ayala ◽  
Enrique Gonzalez-Billalabeitia ◽  
Elena Vicente ◽  
Pedro Gonzalez-Cabezas ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Medical Oncology ◽  
Therapeutic Management ◽  
Whole Body ◽  
Oncology Patients ◽  
18F Fdg

scholarly journals Preliminary experience with 18f-fluoro-deoxy-glucose positron emission tomography/computed tomography in pediatric oncology patients

2011 ◽  
Vol 58 (4) ◽  
pp. 67-73
Author(s):  
Strahinja Odalovic ◽  
Dragana Sobic-Saranovic ◽  
Smiljana Pavlovic ◽  
Isidora Grozdic ◽  
Djordjije Saranovic ◽  
...  
Keyword(s):  
Pediatric Oncology ◽  
Fdg Pet ◽  
Pediatric Patients ◽  
Distant Metastases ◽  
Oncology Patients ◽  
Positron Emission ◽  
Clinical Center ◽  
Pet Ct ◽  
Residual Masses ◽  
Fdg Pet Ct

The aim of this study was to present preliminary experience with FDG PET/CT in pediatric oncology patients in National PET Center, Clinical Center of Serbia and to asses its impact on management of malignancies in children. 33 FDG PET /CT scans were performed on 30 pediatric patients. PET/CT imaging was performed for staging the disease, assessing therapy efficacy and diagnosing recurrent or metastatic disease. FDG PET/CT changed the stage of the disease in 60.6 % (20/33) of the cases. 14 patients were down-staged after PET/CT, mostly patients with Hodgkin?s disease, were in 7/10 cases PET/CT showed no activity in residual masses. Six scans led to upstage of the disease. In three cases PET/CT did not change the stage of disease, but has showed new distant metastases. In conclusion, FDG PET/CT showed important role in managing pediatric patients with different malignancies and was useful complementary diagnostic tool to conventional imaging methods.

scholarly journals Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up18F-FDG PET/CT Scans in Oncology Patients

2016 ◽  
Vol 58 (5) ◽  
pp. 737-743 ◽  
Author(s):  
Mehdi Taghipour ◽  
Charles Marcus ◽  
Sara Sheikhbahaei ◽  
Esther Mena ◽  
Shwetha Prasad ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Ct Scans ◽  
Oncology Patients ◽  
Clinical Indications ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients

2015 ◽  
Vol 42 (13) ◽  
pp. 2072-2082 ◽  
Author(s):  
Elske Quak ◽  
Pierre-Yves Le Roux ◽  
Michael S. Hofman ◽  
Philippe Robin ◽  
David Bourhis ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Lesion Detection ◽  
Oncology Patients ◽  
Pet Quantification

scholarly journals Reducing Radiation Exposure to Paediatric Patients Undergoing [18F]FDG-PET/CT Imaging

2021 ◽  
Author(s):  
Hunor Kertész ◽  
Thomas Beyer ◽  
Kevin London ◽  
Hamda Saleh ◽  
David Chung ◽  
...  
Keyword(s):  
Image Quality ◽  
Fdg Pet ◽  
Signal To Noise Ratio ◽  
Paediatric Oncology ◽  
Whole Body ◽  
Oncology Patients ◽  
Pet Ct ◽  
18F Fdg ◽  
Noise Ratio ◽  
Fdg Pet Ct

Abstract Purpose To investigate the possibility of reducing the injected activity for whole-body [18F]FDG-PET/CT studies of paediatric oncology patients and to assess the usefulness of time-of-flight (TOF) acquisition on PET image quality at reduced count levels. Procedures Twenty-nine paediatric oncology patients (12F/17M, 3–18 years old (median age 13y), weight 45±20 kg, BMI 19±4 kg/m2), who underwent routine whole-body PET/CT examinations on a Siemens Biograph mCT TrueV system with TOF capability (555ps) were included in this study. The mean injected activity was 156 ± 45 MBq (3.8 ± 0.8 kg/MBq) and scaled to patient weight. The raw data was collected in listmode (LM) format and pre-processed to simulate reduced levels of [18F]FDG activity (75, 50, 35, 20 and 10% of the original counts) by randomly removing events from the original LM data. All data were reconstructed using the vendor-specific e7-tools with standard OSEM only, with OSEM plus resolution recovery (PSF). The reconstructions were repeated with added TOF (TOF) and PSF+TOF. The benefit of TOF together with the reduced count levels was evaluated by calculating the gains in signal-to-noise ratio (SNR) in the liver and contrast-to-noise ratio (CNR) in all PET-positive lesions before and after TOF employed at every simulated reduced count level. Finally, the PSF+TOF images at 50, 75 and 100% of counts were evaluated clinically on a 5-point scale by three nuclear medicine physicians. Results The visual inspection of the reconstructed images did not reveal significant differences in image quality between 75 and 100% count levels for PSF+TOF. The improvements in SNR and CNR were the greatest for TOF reconstruction and PSF combined. Both SNR and CNR gains did increase linearly with the patients BMI for both OSEM only and PSF reconstruction. These benefits were observed until reducing the counts to 50 and 35% for SNR and CNR, respectively. Conclusions The benefit of using TOF was noticeable when using 50% or greater of the counts when evaluating the CNR and SNR. For [18F]FDG-PET/CT, whole-body paediatric imaging the injected activity can be reduced to 75% of the original dose without compromising PET image quality.

Sign in / Sign up

Export Citation Format

Share Document